Shreeram Aradhye, M.D., joined Dicerna in September 2020 from Axcella Health where he served as Executive Vice President and Chief Development Officer overseeing clinical development, regulatory affairs, quality assurance and scientific communications.
Prior to joining Axcella, Dr. Aradhye served for over two decades at Novartis Pharmaceuticals in multiple leadership roles of increasing responsibility in drug development and medical affairs, and across multiple therapeutic areas and geographies. In his most recent role as Chief Medical Officer of Novartis, he was a member of the Global Pharmaceuticals Executive Committee responsible for over $20 billion in worldwide business, providing medical expertise on portfolio strategy and leading governance of medical activities worldwide. Dr. Aradhye was also a member of the development committee of Novartis that oversaw global development activities across its portfolio. In previous roles at Novartis and Sandoz, he led the clinical development program for Gilenya® in multiple sclerosis (MS), provided functional leadership for clinical development and medical affairs teams working on novel and biosimilar medicines across multiple therapeutic areas, and headed global development for neuroscience, where he oversaw a portfolio of programs in MS, Alzheimer’s Disease, neuropathic pain, muscle disease and migraine.
Prior to industry, Dr. Aradhye was Assistant Professor of Medicine and a transplant nephrologist at the University of Pennsylvania. Dr. Aradhye received his medical education at the All India Institute of Medical Sciences in New Delhi, India, and in Internal Medicine and Nephrology in the United States.
How do I contact Shreeram Aradhye?
Has Shreeram Aradhye been buying or selling shares of Dicerna Pharmaceuticals?
Shreeram Aradhye has not been actively trading shares of Dicerna Pharmaceuticals over the course of the past ninety days. Most recently, Shreeram Aradhye sold 2,056 shares of the business's stock in a transaction on Friday, September 17th. The shares were sold at an average price of $21.47, for a transaction totalling $44,142.32. Learn More on Shreeram Aradhye's trading history.
Who are Dicerna Pharmaceuticals' active insiders?
